About Palbociclib API
Therapeutic CategoryAnti-Cancer/ Oncology

CAS Number
571190-30-2
API Technology
Synthetic
Dose Form
Capsule/ Tablet, Oral Solids
Dr Reddy's Development Status
Available
Available Regulatory Filing
Brazil DMF, USDMF, Singapore DMF
Mechanism of Action
It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Indication
IBRANCE is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
- An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
- Fulvestrant in women with disease progression following endocrine therapy.
Related APIs
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!